Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

devatis limited - granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg - solution for injection - 1 mg/ml - active: granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg excipient: citric acid monohydrate hydrochloric acid sodium chloride sodium hydroxide water for injection - for the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy in adults for the prevention of nausea and vomiting induced by cytotoxic chemotherapy in children

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

devatis limited - hydroxycarbamide 500mg;  ;   - capsule - 500 mg - active: hydroxycarbamide 500mg     excipient: citric acid dibasic sodium phosphate erythrosine gelatin indigo carmine lactose monohydrate magnesium stearate quinoline yellow titanium dioxide - significant tumor response to hydroxycarbamide (hydroxyurea) has been demonstrated in melanoma, resistant chronic myelocytic leukemia, and recurrent metastatic or inoperable carcinoma of the ovary. hydroxycarbamide used concomitantly with irradiation therapy is intended for use in the local control of primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip, and carcinoma of the cervix.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

devatis limited - ambrisentan 10mg - film coated tablet - 10 mg - active: ambrisentan 10mg excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry pink 85g540055 - indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary arterial hypertension associated with connective tissue disease (pah-ctd), in patients with who functional class ii, iii or iv symptoms.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

devatis limited - ambrisentan 5mg - film coated tablet - 5 mg - active: ambrisentan 5mg excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry pink 85g540056 - indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary arterial hypertension associated with connective tissue disease (pah-ctd), in patients with who functional class ii, iii or iv symptoms.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

devatis limited - iloprost 0.01 mg/ml - solution for inhalation - 20 mcg/2ml - active: iloprost 0.01 mg/ml excipient: ethanol hydrochloric acid sodium chloride trometamol water for injection - treatment of patients with primary pulmonary hypertension or secondary pulmonary hypertension due to connective tissue disease or drug-induced, in moderate or severe stages of the disease. in addition, treatment of moderate or severe secondary pulmonary hypertension due to chronic pulmonary thromboembolism, where surgery is not possible.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

devatis limited - chloramphenicol 10 mg/g - eye ointment - 1% w/w - active: chloramphenicol 10 mg/g excipient: liquid paraffin white soft paraffin - for the treatment of bacterial conjunctivitis. for use under medical supervision only in the treatment of other superficial ocular infections caused by chloramphenicol-sensitive organisms

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

devatis limited - clopidogrel besilate 111.85mg equivalent to 75 mg clopidogrel;   - film coated tablet - 75 mg - active: clopidogrel besilate 111.85mg equivalent to 75 mg clopidogrel   excipient: crospovidone ethylcellulose hydrogenated castor oil isopropyl alcohol macrogol 6000   microcrystalline cellulose titanium dioxide - prevention of vascular ischaemia associated with atherothrombotic events (mi, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

devatis limited - fluticasone propionate 15mg equivalent to 125 mcg/dose; salmeterol xinafoate 4.356mg equivalent to 25 mcg/dose salmeterol - aerosol inhaler, metered dose - active: fluticasone propionate 15mg equivalent to 125 mcg/dose salmeterol xinafoate 4.356mg equivalent to 25 mcg/dose salmeterol excipient: norflurane - indicated for the regular treatment of asthma (reversible obstructive airways disease) in adults and adolescents aged 12 years and over, where use of a combination product (bronchodilator and inhaled corticosteroid) is appropriate.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

devatis limited - fluticasone propionate 30mg equivalent to 250 mcg/dose; salmeterol xinafoate 4.356mg equivalent to 25 mcg/dose salmeterol - aerosol inhaler, metered dose - active: fluticasone propionate 30mg equivalent to 250 mcg/dose salmeterol xinafoate 4.356mg equivalent to 25 mcg/dose salmeterol excipient: norflurane - indicated for the regular treatment of asthma (reversible obstructive airways disease) in adults and adolescents aged 12 years and over, where use of a combination product (bronchodilator and inhaled corticosteroid) is appropriate.

США - англійська - NLM (National Library of Medicine)

devatis, inc. - succinylcholine chloride (unii: i9l0ddd30i) (succinylcholine - unii:j2r869a8yf) - succinylcholine chloride injection, usp is indicated in adults and pediatric patients: - as an adjunct to general anesthesia. - to facilitate tracheal intubation. - to provide skeletal muscle relaxation during surgery or mechanical ventilation. succinylcholine chloride injection, usp is contraindicated: - in patients with skeletal muscle myopathies [see warnings and precautions (5.1)] - in patients with known hypersensitivity to succinylcholine. severe anaphylactic reactions to succinylcholine have been reported [see warnings and precautions (5.2)] - after the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury, which may result in severe hyperkalemia and cardiac arrest [see warnings and precautions (5.4)] - in patients with known or suspected genetic susceptibility to malignant hyperthermia [see warnings and precautions (5.5), clinical pharmacology (12.5)] risk summary available data from published literature from case reports a